XXII Valuation

22nd Century Group Inc

Add to Watchlist

Advanced Chart

1.750

-0.05(-2.778%)1D

Overview
Forecast
Valuation
Earnings

XXII Relative Valuation

XXII's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XXII is overvalued; if below, it's undervalued.

Historical Valuation

22nd Century Group Inc (XXII) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.16 is considered Undervalued compared with the five-year average of -51.37. The fair price of 22nd Century Group Inc (XXII) is between 58.82 to 59.55 according to relative valuation methord. Compared to the current price of 1.75 USD , 22nd Century Group Inc is Undervalued By 97.02%.

Relative Value

Fair Zone

58.82-59.55

Current Price：1.75

97.02%

Undervalued

-0.00

Trailing

Forward

-1.26

EV/EBITDA

22nd Century Group Inc. (XXII) has a current EV/EBITDA of -1.26. The 5-year average EV/EBITDA is -4.47. The thresholds are as follows: Strongly Undervalued below -16.18, Undervalued between -16.18 and -10.32, Fairly Valued between 1.39 and -10.32, Overvalued between 1.39 and 7.24, and Strongly Overvalued above 7.24. The current Forward EV/EBITDA of -1.26 falls within the Historic Trend Line -Fairly Valued range.

-1.06

EV/EBIT

22nd Century Group Inc. (XXII) has a current EV/EBIT of -1.06. The 5-year average EV/EBIT is -5.72. The thresholds are as follows: Strongly Undervalued below -17.27, Undervalued between -17.27 and -11.50, Fairly Valued between 0.06 and -11.50, Overvalued between 0.06 and 5.84, and Strongly Overvalued above 5.84. The current Forward EV/EBIT of -1.06 falls within the Historic Trend Line -Fairly Valued range.

0.16

22nd Century Group Inc. (XXII) has a current PS of 0.16. The 5-year average PS is 4.05. The thresholds are as follows: Strongly Undervalued below -5.63, Undervalued between -5.63 and -0.79, Fairly Valued between 8.88 and -0.79, Overvalued between 8.88 and 13.72, and Strongly Overvalued above 13.72. The current Forward PS of 0.16 falls within the Historic Trend Line -Fairly Valued range.

0.42

P/OCF

22nd Century Group Inc. (XXII) has a current P/OCF of 0.42. The 5-year average P/OCF is -6.18. The thresholds are as follows: Strongly Undervalued below -23.17, Undervalued between -23.17 and -14.67, Fairly Valued between 2.32 and -14.67, Overvalued between 2.32 and 10.82, and Strongly Overvalued above 10.82. The current Forward P/OCF of 0.42 falls within the Historic Trend Line -Fairly Valued range.

0.46

P/FCF

22nd Century Group Inc. (XXII) has a current P/FCF of 0.46. The 5-year average P/FCF is -6.08. The thresholds are as follows: Strongly Undervalued below -22.94, Undervalued between -22.94 and -14.51, Fairly Valued between 2.35 and -14.51, Overvalued between 2.35 and 10.78, and Strongly Overvalued above 10.78. The current Forward P/FCF of 0.46 falls within the Historic Trend Line -Fairly Valued range.

22nd Century Group Inc (XXII) has a current Price-to-Book (P/B) ratio of 0.55. Compared to its 3-year average P/B ratio of 0.13 , the current P/B ratio is approximately 321.00% higher. Relative to its 5-year average P/B ratio of 2.80, the current P/B ratio is about -80.27% higher. 22nd Century Group Inc (XXII) has a Forward Free Cash Flow (FCF) yield of approximately -269.88%. Compared to its 3-year average FCF yield of -396.31%, the current FCF yield is approximately -31.90% lower. Relative to its 5-year average FCF yield of -231.90% , the current FCF yield is about 16.37% lower.

0.55

P/B

Median3y

0.13

Median5y

2.80

-269.88

FCF Yield

Median3y

-396.31

Median5y

-231.90

Competitors Valuation Multiple

The average P/S ratio for XXII's competitors is 23.61, providing a benchmark for relative valuation. 22nd Century Group Inc Corp (XXII) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -26.23%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

XXII.O

22nd Century Group Inc

Ensysce Biosciences Inc

Alaunos Therapeutics Inc

Transcode Therapeutics Inc

64.89

8.11M

Performance Decomposition

Market capitalization of XXII decreased by 99.70% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from -176.72 to -143.91.

The secondary factor is the Revenue Growth, contributed -26.23%to the performance.

Overall, the performance of XXII in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-26.23%

3.08M → 2.28M

Revenue Growth

-18.57%

-176.72 → -143.91

Margin Expansion

-54.90%

-0.05 → -0.02

P/E Change

-99.70%